Korro to Participate in Upcoming Investor and Scientific Conferences
Rhea-AI Summary
Korro Bio (Nasdaq: KRRO) has announced its participation in six major investor and scientific conferences during September 2025. The company's leadership team, including CEO Ram Aiyar, CSO Loic Vincent, CFO Vineet Agarwal, and COO Todd Chappell, will engage in various activities across these events.
Key events include presentations at the Cantor Global Healthcare Conference and the RNA Leaders USA Congress, where they will discuss RNA editing therapies. The management team will also conduct one-on-one investor meetings at multiple conferences, including Citi's Biopharma Back to School Conference, Wells Fargo Securities Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference.
Positive
- None.
Negative
- None.
News Market Reaction 37 Alerts
On the day this news was published, KRRO gained 17.25%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.6% during that session. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $38M to the company's valuation, bringing the market cap to $257M at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:
Citi's 2025 Biopharma Back to School Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025.
Cantor Global Healthcare Conference
Dr. Aiyar will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 p.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.
2025 Wells Fargo Securities Healthcare Conference
Dr. Vincent and Todd Chappell, Chief Operating Officer, will participate in 1x1 investor meetings on Friday, September 5, 2025.
H.C. Wainwright 27th Annual Global Investment Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
Morgan Stanley 23rd Annual Global Healthcare Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
RNA Leaders USA Congress
Mr. Chappell will deliver a presentation titled, “Developing Novel RNA Editing Therapies to Address Unmet Needs for Rare and Highly Prevalent Diseases,” on Thursday, September 11, 2025, at 11:45 a.m. ET.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Korro Bio (KRRO) presenting at the Cantor Global Healthcare Conference 2025?
What will be the topic of Korro Bio's presentation at the RNA Leaders USA Congress 2025?
Which Korro Bio executives are participating in the Morgan Stanley Healthcare Conference 2025?
How many conferences is Korro Bio (KRRO) attending in September 2025?
